Buprenorphine and methadone for opioid addiction during pregnancy

Obstetrics and Gynecology Clinics of North America

Volumn 41, Issue 2, 2014, Pages 241-253

  Mozurkewich, Ellen L ^a   Rayburn, William F ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Abstinence; Buprenorphine; Methadone; Neonatal; Pregnancy opioid addiction

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; METHADONE; MORPHINE; OXYCODONE; NARCOTIC ANALGESIC AGENT;

ABSENCE OF SIDE EFFECTS; BREAST FEEDING; CHILD BEHAVIOR; CHILD DEVELOPMENT; DISEASE DURATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DETOXIFICATION; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TISSUE LEVEL; DRUG TRANSPORT; DRUG WITHDRAWAL; FETUS DEVELOPMENT; FETUS OUTCOME; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; KIDNEY CLEARANCE; MAINTENANCE THERAPY; MATERNAL CARE; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; OUTCOME ASSESSMENT; PATIENT COUNSELING; PATIENT PREFERENCE; PATIENT SELECTION; POSTNATAL CARE; POSTOPERATIVE PAIN; PREGNANCY; PREGNANCY OUTCOME; PREGNANT WOMAN; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SECOND TRIMESTER PREGNANCY; SINGLE DRUG DOSE; THIRD TRIMESTER PREGNANCY; WITHDRAWAL SYNDROME; DRUG ADMINISTRATION; FEMALE; NEONATAL ABSTINENCE SYNDROME; OPIOID-RELATED DISORDERS; PRACTICE GUIDELINE; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE; PROCEDURES; PSYCHOLOGY; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME;

ANALGESICS, OPIOID; BUPRENORPHINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; METHADONE; NEONATAL ABSTINENCE SYNDROME; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANT WOMEN; PRENATAL EXPOSURE DELAYED EFFECTS; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME;

EID: 84900801607     PISSN: 08898545     EISSN: 15580474     Source Type: Journal    
DOI: 10.1016/j.ogc.2014.02.005     Document Type: Review

References (66)

1. Young J.L., Martin P.R. Treatment of opioid dependence in the setting of pregnancy. Psychiatr Clin North Am 2012, 35(2):441-460.
2. Albright B., de la Torre L., Skipper B., et al. Changes in methadone maintenance therapy during and after pregnancy. J Subst Abuse Treat 2011, 41(4):347-353.
3. Jones H.E., Deppen K., Hudak M.L., et al. Clinical care for opioid-using pregnant and postpartum women: the role of obstetric providers. Am J Obstet Gynecol 2014, 210(4):302-310.
4. ACOG Committee on Health Care for Underserved Women, American Society of Addiction Medicine ACOG Committee Opinion No. 524: opioid abuse, dependence, and addiction in pregnancy. Obstet Gynecol 2012, 119(5):1070-1076.
5. Katz D.F., Sun J., Khatri V., et al. QTc interval screening in an opioid treatment program. Am J Cardiol 2013, 112(7):1013-1018.
6. Shiu J.R., Ensom M.H. Dosing and monitoring of methadone in pregnancy: literature review. Can J Hosp Pharm 2012, 65(5):380-386.
7. Jansson L.M., Dipietro J.A., Velez M., et al. Maternal methadone dosing schedule and fetal neurobehaviour. J Matern Fetal Neonatal Med 2009, 22(1):29-35.
8. Wittmann B.K., Segal S. A comparison of the effects of single- and split-dose methadone administration on the fetus: ultrasound evaluation. Int J Addict 1991, 26(2):213-218.
9. Jones H.E., O'Grady K.E., Malfi D., et al. Methadone maintenance vs. methadone taper during pregnancy: maternal and neonatal outcomes. Am J Addict 2008, 17(5):372-386.
10. Arlettaz R., Kashiwagi M., Das-Kundu S., et al. Methadone maintenance program in pregnancy in a Swiss perinatal center (II): neonatal outcome and social resources. Acta Obstet Gynecol Scand 2005, 84(2):145-150.
11. Markham J.K., Emmerson J.L., Owen N.V. Teratogenicity studies of methadone HCl in rats and rabbits. Nature 1971, 233(5318):342-343.
12. Geber W., Schramm L. Comparative teratogenicity of morphine, heroin, and methadone in the hamster. Pharmacologist 1969, 11:248.
13. Geber W.F., Schramm L.C. Congenital malformations of the central nervous system produced by narcotic analgesics in the hamster. Am J Obstet Gynecol 1975, 123(7):705-713.
14. Jurand A. Teratogenic activity of methadone hydrochloride in mouse and chick embryos. J Embryol Exp Morphol 1973, 30(2):449-458.
15. Ramirez-Cacho W.A., Flores S., Schrader R.M., et al. Effect of chronic maternal methadone therapy on intrapartum fetal heart rate patterns. J Soc Gynecol Investig 2006, 13(2):108-111.
16. Jansson L.M., Dipietro J., Elko A. Fetal response to maternal methadone administration. Am J Obstet Gynecol 2005, 193(3 Pt 1):611-617.
17. Archie C.L., Lee M.I., Sokol R.J., et al. The effects of methadone treatment on the reactivity of the nonstress test. Obstet Gynecol 1989, 74(2):254-255.
18. Levine A.B., Rebarber A. Methadone maintenance treatment and the nonstress test. J Perinatol 1995, 15(3):229-231.
19. Anyaegbunam A., Tran T., Jadali D., et al. Assessment of fetal well-being in methadone-maintained pregnancies: abnormal nonstress tests. Gynecol Obstet Invest 1997, 43(1):25-28.
20. Zuspan F.P., Gumpel J.A., Mejia-Zelaya A., et al. Fetal stress from methadone withdrawal. Am J Obstet Gynecol 1975, 122(1):43-46.
21. Rementeria J.L., Nunag N.N. Narcotic withdrawal in pregnancy: stillbirth incidence with a case report. Am J Obstet Gynecol 1973, 116(8):1152-1156.
22. Stewart R.D., Nelson D.B., Adhikari E.H., et al. The obstetrical and neonatal impact of maternal opioid detoxification in pregnancy. Obstet Gynecol 2013, 209(3):267.e1-267.e5.
23. Blinick G., Jerez E., Wallach R.C. Methadone maintenance, pregnancy, and progeny. JAMA 1973, 225(5):477-479.
24. Carin I., Glass L., Parekh A., et al. Neonatal methadone withdrawal. Effect of two treatment regimens. Am J Dis Child 1983, 137(12):1166-1169.
25. Kempley S. Methadone maintenance treatment. Pregnant women taking methadone should be warned about withdrawal symptoms in babies. BMJ 1995, 310(6977):464.
26. Lim S., Prasad M.R., Samuels P., et al. High-dose methadone in pregnant women and its effect on duration of neonatal abstinence syndrome. Am J Obstet Gynecol 2009, 200(1):70.e1-70.e5.
27. Hussain T., Ewer A.K. Maternal methadone may cause arrhythmias in neonates. Acta Paediatr 2007, 96(5):768-769.
28. Cleary B.J., Donnelly J.M., Strawbridge J.D., et al. Methadone and perinatal outcomes: a retrospective cohort study. Am J Obstet Gynecol 2011, 204(2):139.e1-139.e9.
29. McGlone L., Hamilton R., McCulloch D.L., et al. Neonatal visual evoked potentials in infants born to mothers prescribed methadone. Pediatrics 2013, 131(3):e857-e863.
30. Parikh R., Hussain T., Holder G., et al. Maternal methadone therapy increases QTc interval in newborn infants. Arch Dis Child Fetal Neonatal Ed 2011, 96(2):F141-F143.
31. McGlone L., Hamilton R., McCulloch D.L., et al. Visual outcome in infants born to drug-misusing mothers prescribed methadone in pregnancy. Br J Ophthalmol 2014, 98(2):238-245.
32. Cleary B.J., Eogan M., O'Connell M.P., et al. Methadone and perinatal outcomes: a prospective cohort study. Addiction 2012, 107(8):1482-1492.
33. Pizarro D., Habli M., Grier M., et al. Higher maternal doses of methadone does not increase neonatal abstinence syndrome. J Subst Abuse Treat 2011, 40(3):295-298.
34. Jansson L.M., Velez M., Harrow C. Methadone maintenance and lactation: a review of the literature and current management guidelines. J Hum Lact 2004, 20(1):62-71.
35. Begg E.J., Malpas T.J., Hackett L.P., et al. Distribution of R- and S-methadone into human milk during multiple, medium to high oral dosing. Br J Clin Pharmacol 2001, 52(6):681-685.
36. American Academy of Pediatrics Committee on Drugs Transfer of drugs and other chemicals into human milk. Pediatrics 2001, 108(3):776-789.
37. 1988, 319-320. Elsevier, Philadelphia. The WHO Working Group, P.N. Bennet (Eds.).
38. Jansson L.M., Choo R., Velez M.L., et al. Methadone maintenance and breastfeeding in the neonatal period. Pediatrics 2008, 121(1):106-114.
39. Ballard J.L. Treatment of neonatal abstinence syndrome with breast milk containing methadone. J Perinat Neonatal Nurs 2002, 15(4):76-85.
40. Abdel-Latif M.E., Pinner J., Clews S., et al. Effects of breast milk on the severity and outcome of neonatal abstinence syndrome among infants of drug-dependent mothers. Pediatrics 2006, 117(6):e1163-e1169.
41. Sachs H.C., Committee On Drugs The transfer of drugs and therapeutics into human breast milk: an update on selected topics. Pediatrics 2013, 132(3):e796-e809.
42. Woodward L., Wuick Z.L., Spencer C., et al. Early neurobehavior development of the infant exposed to methadone during pregnancy. Pediatr Res 2006, 3571(2006 PAS Annual Meeting):318.
43. Concheiro M., Jones H.E., Johnson R.E., et al. Preliminary buprenorphine sublingual tablet pharmacokinetic data in plasma, oral fluid, and sweat during treatment of opioid-dependent pregnant women. Ther Drug Monit 2011, 33(5):619-626.
44. Bell J.R., Butler B., Lawrance A., et al. Comparing overdose mortality associated with methadone and buprenorphine treatment. Drug Alcohol Depend 2009, 104(1-2):73-77.
45. Alto W.A., O'Connor A.B. Management of women treated with buprenorphine during pregnancy. Obstet Gynecol 2011, 205(4):302-308.
46. Center for Substance Abuse Treatment (U.S.). Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication. No (SMA) 04-3939 2004.
47. McNicholas L.F., Holbrook A.M., O'Grady K.E., et al. Effect of hepatitis C virus status on liver enzymes in opioid-dependent pregnant women maintained on opioid-agonist medication. Addiction 2012, 107:91-97.
48. Komaromy M., Silver H., Bohan J., et al. New Mexico treatment guidelines for medical providers who treat opioid addiction using buprenorphine 2012, New Mexico Behavioral Health Collaborative, Santa Fe (NM).
49. Kraus M., Alford D., Kotz M., et al. Statement of the American Society of Addiction Medicine Consensus Panel on the use of buprenorphine in office-based treatment of opioid addiction. J Addict Med 2011, 5(4):254.
50. Minozzi S., Amato L., Bellisario C., et al. Maintenance agonist treatments for opiate-dependent pregnant women. Cochrane Database Syst Rev 2013, (12). CD006318.
51. Jones H.E., Heil S.H., Baewert A., et al. Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review. Addiction 2012, 107:5-27.
52. Jones H.E., Kaltenbach K., Heil S.H., et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med 2010, 363(24):2320-2331.
53. Jones H.E., Fischer G., Heil S.H., et al. Maternal Opioid Treatment: Human Experimental Research (MOTHER)-approach, issues and lessons learned. Addiction 2012, 107(Suppl 1):28-35.
54. Jones H.E., Johnson R.E., Jasinski D.R., et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend 2005, 79(1):1-10.
55. Fischer G., Ortner R., Rohrmeister K., et al. Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. Addiction 2006, 101(2):275-281.
56. Handford C., Kahan M., Srivastava A., et al. Buprenorphine/naloxone for opioid dependence: clinical practice guideline 2011, Centre for Addiction and Mental Health, Toronto.
57. O'Connor A., Alto W., Musgrave K., et al. Observational study of buprenorphine treatment of opioid-dependent pregnant women in a family medicine residency: reports on maternal and infant outcomes. J Am Board Fam Med 2011, 24(2):194-201.
58. Bartu A.E., Ilett K.F., Hackett L.P., et al. Buprenorphine exposure in infants of opioid-dependent mothers at birth. Aust N Z J Obstet Gynaecol 2012, 52(4):342-347.
59. Reprotox. Buprenorphine. In: An information system on environmental hazards to human reproduction and development. 2013. Available at: Accessed January 27, 2014. http://reprotox.org/Members/AgentDetail.aspx?a=2726.
60. Salisbury A.L., Coyle M.G., O'Grady K.E., et al. Fetal assessment before and after dosing with buprenorphine or methadone. Addiction 2012, 107:36-44.
61. Welle-Strand G.K., Skurtveit S., Jones H.E., et al. Neonatal outcomes following in utero exposure to methadone or buprenorphine: a National Cohort Study of opioid-agonist treatment of Pregnant Women in Norway from 1996 to 2009. Drug Alcohol Depend 2013, 127(1-3):200-206.
62. Jones H.E., O'Grady K.E., Johnson R.E., et al. Infant neurobehavior following prenatal exposure to methadone or buprenorphine: results from the neonatal intensive care unit network neurobehavioral scale. Subst Use Misuse 2010, 45(13):2244-2257.
63. Coyle M.G., Salisbury A.L., Lester B.M., et al. Neonatal neurobehavior effects following buprenorphine versus methadone exposure. Addiction 2012, 107(Suppl 1):63-73.
64. Ilett K.F., Hackett L.P., Gower S., et al. Estimated dose exposure of the neonate to buprenorphine and its metabolite norbuprenorphine via breastmilk during maternal buprenorphine substitution treatment. Breastfeed Med 2012, 7:269-274.
65. Toxnet. Buprenorphine. In: Toxicology Data Network, U.S. National Library of Medicine. Available at: Accessed January 27, 2014. http://toxnet.nlm.nih.gov/.
66. Jansson L.M. ABM clinical protocol #21: guidelines for breastfeeding and the drug-dependent woman. Breastfeed Med 2009, 4(4):225-228.